[Skip to Navigation]
Views 595
Citations 0
Guide to Statistics and Methods
Reporting Guidelines
April 7, 2021

ISPOR Reporting Guidelines for Comparative Effectiveness Research

Author Affiliations
  • 1Houston Center for Innovations in Quality, Effectiveness and Safety, Michael E. DeBakey VA Medical Center, Houston, Texas
  • 2Division of Surgical Oncology, Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, Texas
  • 3Department of Emergency Medicine, Denver Health Medical Center, University of Colorado School of Medicine, Denver
  • 4Department of Epidemiology, Colorado School of Public Health, Aurora
  • 5Statistical Editor, JAMA Surgery
  • 6Department of Surgery, University of Michigan, Ann Arbor
  • 7Institute for Healthcare Policy and Innovation, University of Michigan, Ann Arbor
JAMA Surg. Published online April 7, 2021. doi:10.1001/jamasurg.2021.0534

Randomized clinical trials (RCTs) are considered the main source of data driving evidence-based practice and the primary method for establishing the efficacy of an intervention. However, for a variety of reasons, the universe of research questions that can be definitively addressed by traditional RCTs is limited.1 At the heart of comparative effectiveness research (CER) is a desire to generate real-world evidence demonstrating the effectiveness (rather than the efficacy) of an intervention using real-world data (obtained outside the often-ideal conditions of a traditional RCT). As value-based reimbursement models are better integrated into the US health care system and patient-centered care is increasingly emphasized, there will be a greater need for high-quality CER studies to inform the most clinically effective and cost-effective treatments and to help identify the right type of treatment for patients being treated in specific clinical contexts.

Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words